

**Supplementary Table 5.** Crude hazard ratios of clinical outcomes with a quarantine period of 6 weeks with binary time-dependent exposure (full cohort)

	Stroke/SE/death (185 events)	Stroke/SE (17 events)	Death (174 events)	Recurrent intracranial bleeding (48 events)	Major extracranial bleeding (21 events)
Exposure to OACs					
No exposure (reference)					
Exposure	0.11 (0.06–0.23)	0.53 (0.15–1.85)	0.07 (0.03–0.18)	0.45 (0.20–1.01)	1.63 (0.67–3.95)
Age (yr)					
65–74 (reference)					
≥75	2.36 (1.25–4.46)	1.03 (0.27–4.49)	2.76 (1.36–5.62)	0.56 (0.27–1.15)	2.94 (0.40–21.80)
Sex					
Male (reference)					
Female	0.78 (0.59–1.03)	4.25 (1.23–14.66)	0.72 (0.53–0.96)	1.21 (0.69–2.11)	2.57 (1.02–6.48)
Prior thromboembolism (stroke/TIA/SE)*					
1.18 (0.73–1.89)	1.35 (0.31–5.85)	1.18 (0.73–1.93)	0.66 (0.21–2.13)	1.52 (0.45–5.08)	
Prior major bleeding (except ICH)*					
1.29 (0.83–2.01)	1.25 (0.29–5.44)	1.32 (0.84–2.07)	1.61 (0.72–3.57)	3.51 (1.39–8.85)	
Chronic heart failure*					
1.69 (1.28–2.24)	0.70 (0.25–1.96)	1.80 (1.35–2.41)	0.88 (0.49–1.58)	1.82 (0.82–4.07)	
Peripheral artery disease*					
1.07 (0.77–1.50)	0.69 (0.20–2.37)	1.15 (0.82–1.62)	0.73 (0.36–1.50)	1.74 (0.75–4.07)	
Chronic kidney disease*					
1.68 (1.27–2.24)	1.60 (0.64–4.04)	1.64 (1.23–2.20)	0.91 (0.52–1.61)	1.89 (0.85–4.23)	
Hypertension*					
0.99 (0.66–1.49)	2.74 (0.37–20.65)	0.95 (0.63–1.44)	0.73 (0.36–1.50)	1.76 (0.41–7.46)	
Dyslipidemia*					
0.93 (0.70–1.24)	0.72 (0.27–1.91)	0.90 (0.67–1.22)	0.78 (0.44–1.39)	2.03 (0.90–4.57)	
Diabetes*					
1.31 (0.98–1.75)	1.10 (0.41–2.93)	1.29 (0.95–1.74)	0.66 (0.35–1.26)	2.22 (1.00–4.94)	
Beta-blockers*					
1.32 (0.99–1.77)	0.96 (0.38–2.44)	1.36 (1.01–1.85)	0.72 (0.41–1.24)	1.54 (0.66–3.59)	
Statins*					
0.88 (0.66–1.17)	1.16 (0.46–2.93)	0.84 (0.63–1.12)	0.82 (0.47–1.42)	1.30 (0.58–2.92)	
NSAIDs*					
0.38 (0.12–1.18)	Not to small	0.41 (0.13–1.28)	1.02 (0.25–4.20)	1.04 (0.14–7.74)	
Proton-pump inhibitors*					
1.60 (1.20–2.12)	1.48 (0.58–3.75)	1.62 (1.20–2.17)	1.02 (0.59–1.77)	1.39 (0.62–3.11)	
Digoxin*					
1.38 (1.02–1.87)	2.99 (1.19–7.53)	1.32 (0.96–1.81)	1.11 (0.60–2.06)	2.15 (0.96–4.84)	
Score Charlson					
<4 (reference)					
≥4	1.77 (1.31–2.39)	1.35 (0.52–3.48)	1.77 (1.30–2.41)	0.80 (0.46–1.39)	1.72 (0.74–4.01)
CHA <sub>2</sub> DS <sub>2</sub> -VASc score					
<3 (reference)					
≥3	1.06 (0.72–1.56)	3.31 (0.44–24.89)	1.01 (0.68–1.50)	0.76 (0.38–1.52)	4.48 (0.60–33.14)
HAS-BLED score					
<3 (reference)					
≥3	1.22 (0.92–1.62)	0.83 (0.31–2.20)	1.28 (0.95–1.72)	1.05 (0.60–1.84)	2.33 (1.04–2.25)
Length of stay					
1.01 (0.99–1.02)	1.02 (0.98–1.06)	1.01 (0.99–1.02)	1.00 (0.97–1.03)	1.00 (0.96–1.04)	

Values are presented as hazard ratio (95% confidence interval).

SE, systemic embolism; OAC, oral anticoagulant; TIA, transient ischemic attack; ICH, intracranial hemorrhage; NSAID, nonsteroidal anti-inflammatory drug.

\*1=yes vs. 0=no.